Oral GLP-1 Therapies
10 articles on Oral GLP-1 Therapies, researched and written by the Shotlee Editorial Team from primary sources.
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
Structure's GLP-1 Pill Shows 16% Weight Loss in Phase 2 Trial
Structure Therapeutics announced impressive Phase 2 results for its daily obesity pill, with patients losing about 16% of their body weight compared to placebo after 44 weeks. This positions the company to challenge leaders like Eli Lilly and Novo Nordisk in the race for effective oral GLP-1 therapies. Discover the details and implications for obesity treatment.
4 min read
Study Explores Plant-Based Platform for Oral GLP-1 Therapies
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
6 min read
Billion-Dollar Longevity Business: Adding Years to Life
The aging population's Silver Tsunami is reshaping global economies, but the Longevity Investors Lunch offers a beacon of innovation. From ultra-personalized medicine to bio-avatars and surging GLP-1 valuations, investors are betting billions on extending healthy lifespans. Yet, warnings about risky supplements highlight the path ahead.
6 min read
Wegovy Pill Launch: 18K+ Prescriptions in Debut Week
Novo Nordisk's Wegovy pill smashed expectations with over 18,000 prescriptions in its debut week, signaling a shift toward oral GLP-1 therapies. This needle-free semaglutide option offers flexibility for weight management, but how does it stack up against injectables? Explore the data, science, and what it means for patients.
5 min read
Wegovy Oral Tablet Lands in US, Delivering Innovative Pill-Based Solution for Weight Management
The United States now offers an additional avenue for weight reduction as Novo Nordisk introduces its Wegovy oral medication across the country. This daily tablet, featuring semaglutide, represents the initial and sole GLP-1 pill for adults, simplifying obesity management without injections. Clinical studies indicate notable weight loss, though side effects may occur.
2 min read